Physician profile
Matthew Hamar
NPI 1154618130
$2,078.70
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $190 · 2021: $574 · 2022: $970.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $270.01 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $224.88 | 2019-2022 | |
| Astellas Pharma US INC | $205.68 | 2019-2022 | |
| Abbvie INC. | $194.68 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $172.63 | 2021-2022 | |
| Pfizer INC. | $144.17 | 2020-2022 | |
| Novo Nordisk INC | $143.48 | 2019-2022 | |
| Lilly USA, LLC | $140.26 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $134.75 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $89.99 | 2019-2022 | |
| Abbott Laboratories | $83.32 | 2020-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $79.58 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.52 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.43 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $38.37 | 2020-2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $14.81 | 2020 | |
| Allergan, INC. | $12.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Hamar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.